News in brief: DOACs could replace warfarin in heart pumps; Therapeutic plasma exchange for refractory VITT; Polatuzumab as salvage and bridging treatment in r/r LBCL;

DOACs could replace warfarin in heart pumps DOACs could potentially replace warfarin as the anticoagulants used in a left ventricular assist device for heart failure, an Australian study suggests. In vitro tests conducted by researchers at the Heart and Lung Transplant Unit, St. Vincent’s Hospital, Sydney, showed that apixaban was at least as effective as ...

Already a member?

Login to keep reading.

© 2021 the limbic